ICJIM

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Index
Case Report
Management of pulmonary tuberculosis and hypersensitivity reaction to antituberculosis drugs in a patient presenting with recurrent psoas abscess
Psoas abscess is a difficult disease to diagnose. MTB can cause psoas abscess. First generation anti-TB drugs are used in the treatment of TB, side effects may occur during treatment; one of these side effects is hypersensitivity reactions. In this case report, we aimed to present a patient who presented with recurrent psoas abscess occurs after pulmonary tuberculosis and developed hypersensitivity reaction to antituberculosis drugs and the treatment method we applied. A 44-year-old male patient presented with fever, cough and right flank pain. It was learned that he had hypothyroidism and received antibiotherapy and drainage treatment for recurrent psoas abscesses. His family history was unremarkable and respiratory sounds were normal. Fever was 37.8 °C. WBC: 6.640/mm³, CRP: 70mg/L, ESR: 33mm/h. Liver dynamic CT showed psoas abscess, drainage was provided.Pulmonary tuberculosis was thought to be the etiology of recurrent psoas abscess, thorax CT was ordered and culture and aside resitant staining (ARS) were sent from sputum and abscess upon observation of infiltrations.(Figure 1) No growth was observed in abscess culture and MTB was not detected. With the initiation of HRZE treatment, the patient developed sudden dyspnea, high fever, and skin rashes, and the treatment was terminated. Premedication was decided to be performed before the drug and progressive drug loading was performed to determine the responsible drug. The patient, who had no new allergic reaction during the treatment period, was discharged and methylprednisolone tablets were prescribed for 21 days, bilastine and desloratadine tablets were prescribed for 6 months together with TB drugs. Tuberculosis is among the important causes of morbidity and mortality in developing countries. At the beginning of treatment, patients should be told about the side effects that may occur with the drugs they use. In patients who develop hypersensitivity reactions, temporary or permanent discontinuation of drugs and often hospitalization of the patient is required. Antihistamines and steroids may need to be used for the control of severe reactions.In our case, we wanted to emphasize that patients may develop tuberculosis even if they do not present with pulmonary symptoms and that drug side effects should always be kept in mind and the necessity and importance of premedication and gradual drug loading therapy in patients with hypersensitivity reactions.


1. World Health Organization. “Global tuberculosis report 2018. 2018. “Geneva: World Health Organization (2019).
2. Muneer A, Macrae B, Krishnamoorthy S, Zumla A. Urogenital tuberculosis - epidemiology, pathogenesis and clinical features.<em>Nat Rev Urol</em>. 2019;16(10):573-598. doi:10.1038/s41585-019-0228-9
3. Furin J, Cox H, Pai M. Tuberculosis.<em>Lancet</em>. 2019;393(10181):1642-1656. doi:10.1016/S0140-6736(19)30308-3
4. Kara F. Tuberculosis Diagnosis and Treatment Guide. Ankara, Ministry of Health, 2019.
5. Gruenwald I, Abrahamson J, Cohen O. Psoas abscess: case report and review of the literature. <em>J Urol.</em> 1992;147(6):1624-1626.
6. Thomas A, Albert AS, Bhat S, Sunil KR. Primary psoas abscess--diagnostic and therapeutic considerations.<em>Br J Urol</em>. 1996;78(3):358-360.
7. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy.<em>Tubercle</em>. 1985;66(3):219-225. doi:10.1016/0041-3879(85)90040-6
8. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease.<em>Soc Appl Bacteriol Symp Ser</em>. 1996;25:72S-80S.
9. Girling DJ. Adverse effects of antituberculosis drugs.<em>Drugs</em>. 1982;23(1-2):56-74. doi:10.2165/00003495-198223010-00003
10. Harries A. What are the most common adverse drug events to first-line tuberculosis drugs, and what is the procedure for reintroduction of drugs? In ed. T. Frieden. Toman&rsquo;s tuberculosis case detection, treatment, and monitoring : questions and answers.- 2nd ed. p. 152-158.
Volume 2, Issue 4, 2024
Page : 106-109
_Footer